The study also reveals that this inhibition occurs through the targeting of ETS1 via the PI3K/AKT/mTOR pathway and this implies that SNHG6 might act as a tumor suppressor in the context of colorectal cancer, as opposed to its oncogenic role in other cancer types. Here, SNHG6 is linked to cancer.